[ May 10 (Thu) ]
Global Market Strategy for Biosimilar


A fresh eyes perspective of Korean biosimilar business, the global market leader : If we have made a successful entry based on technological strengths, it is time to make breakthroughs for quality management and mass production. This session will provide in-depth insights on biosimilar development from diverse angles to enlighten the path forward to advancing and revamping the biosimilar success stories


Session Chair Jean Paul Deslypere, Professor, Dept of Medicine, University Hospital of Gent, Belgium
Time Session Title
09 : 30 ~ 10 : 10 Biosimilar Market Outlook - The Most Competitive Technology Evolution
Jean Paul Deslypere, Professor, Dept of Medicine, University Hospital of Gent, Belgium
10 : 10 ~ 10 : 40 Designing a Protein Supply Chain That Meets Flexibility, Timelines, Performance
Hugo DeWit, Managing Director, Business Deve, Sartorius Stedim Cellca GmbH
10 : 40 ~ 11 : 10 The Smartfactory, End to End Modular Automation
John Moys , Director, Enterprise Sales Solutions , Thermo Scientific Finesse BioProduction
11 : 10 ~ 11 : 40 Evaluation of A Highly Alkali Stable Protein A Resin for Improved Purification of Monoclonal Antibodies
Jae Hyun Kim, Director, Bio Technology, GE Healthcare
Panel Discussion
11 : 40 ~ 12 : 15 Discussion about Biosimilar Regulation
Michael Kim, CEO, Prestige Bio
John Moys, Director, Enterprise Sales Solutions, Thermo Scientific Finesse BioProduction
Jin Pub Son, Director, Business Planning Team, DM BIo Limited
Hugo DeWit, Managing Director, Business Deve, Sartorius Stedim Cellca GmbH
Bang Kue Ho, Professor, Pharmaceutical Engineering, Gyeongnam National University of Science and Technology